Safety information on medicines for healthcare professionals sent in June 2008

Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.

A list of letters sent to healthcare professionals in June 2008 informing of new safety information and advice.

Date issued
Product
Safety information
 18/06/2008 Exubera (inhaled human insulin)

Availability update: Exubera will not be available in the near future for commercial reasons
Safety update: Reports of newly diagnosed cases of primary lung malignancy in a clinical trial programme

› Letter for GPs and diabetologistsPDF file (opens in new window) (2880Kb)
› Letter for investigators of Exubera who will be invited to participate in a follow-up cohort studyPDF file (opens in new window) (4504Kb)
› Letter for pharmacists and dispensing doctors who have received Exubera deliveries in past 6 monthsPDF file (opens in new window) (3885Kb)
13/06/2008
Thalidomide Pharmion

Pregnancy Prevention Programme and supply of unlicensed medicine to meet the special needs of individual patients

› Pregnancy Prevention ProgrammePDF file (opens in new window) (150Kb)
› Risk management planPDF file (opens in new window) (115Kb)
10/06/2008
Rotigotine patch (Neupro)

New prescribing and storage requirements

› Physician letterPDF file (opens in new window) (22Kb)
› Pharmacist letterPDF file (opens in new window) (25Kb)

Page last modified: 24 July 2008